The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda

  • Grant Dorsey
  • , Anne F. Gasasira
  • , Rhoderick Machekano
  • , Moses R. Kamya
  • , Sarah Staedke
  • , Alan Hubbard

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

Antimalarial drug treatment policy in sub-Saharan Africa is generally guided by the results of clinical drug efficacy studies in patients with uncomplicated Plasmodium falciparum malaria. The selection criteria used to enroll these patients often vary and may have a significant impact on treatment outcomes. In Kampala, Uganda, we investigated the impact of age, baseline temperature, and pre-treatment parasite density on estimates of treatment efficacy using a statistical modeling approach in 2,138 patients enrolled in six clinical trials involving seven different treatment regimens. Decreasing age, increasing temperature, and increasing parasite density were all independent predictors of an increased risk of treatment failure across all treatment groups. Compared with an unrestrictive approach to subject selection, enrolling only patients fulfilling selection criteria recommended by the World Health Organization (age < 5 years old, documented fever, and parasite density < 200,000/μL) increased the risk of treatment failure by 25-60% for the different treatment regimens. Caution should be taken when comparing results from drug efficacy studies with different subject selection criteria.
Original languageEnglish
Pages (from-to)531-536
Number of pages6
JournalThe American Journal of Tropical Medicine and Hygiene
Volume71
Issue number5
DOIs
Publication statusPublished - 1 Nov 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda'. Together they form a unique fingerprint.

Cite this